You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK):完成季節性流感疫苗在巴西的上市申報
格隆匯 11-07 07:48

格隆匯11月7日丨三葉草生物-B(02197.HK)發佈公吿,在公司已完成向巴西國家衞生監督管理局基於其季節性流感疫苗的上市申報。一旦獲批,公司將與巴西當地合作伙伴展開進一步合作,在巴西實現該流感疫苗的商業化。

一旦該疫苗在巴西獲批,公司季節性流感疫苗的商業化將擴張至南半球,贏得南半球上半年流感季的銷售市場,這將與中國等北半球下半年流感季的銷售市場相互補充,使本公司的季節性流感疫苗贏得全年的銷售週期並增加可持續性收益,同時還能更充分地利用國光生物科技股份有限公司全年的生產能力。就市場戰略而言,巴西是一個重要的疫苗市場,根據GlobalData,巴西是世界第二大季節性流感疫苗市場,預計未來五年當地的總市場空間將超過10億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account